Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 221Polycystic Ovary Syndrome 36Endometrial Neoplasms 15Ovarian Neoplasms 13Infertility 11Neoplasm Metastasis 9Carcinoma, Intraductal, Noninfiltrating 7Fallopian Tube Neoplasms 6Neoplasms 5Breast Diseases 5Triple Negative Breast Neoplasms 4Osteoporosis 4Leiomyoma 4Infertility, Female 4Breast Neoplasms, Male 4Breast Carcinoma In Situ 4Arthralgia 4Advanced Breast Cancer 4Recurrence 3Obesity 3Breast Cancer Metastatic 3Anovulation 3Uterine Neoplasms 2Solid Tumor 2Prostatic Neoplasms 2Progesterone Resistance 2Pancreatic Neoplasms 2Pain 2Leiomyosarcoma 2HR Positive HER2 Negative Advanced Breast Cancer 2

Interventions

Letrozole 2exemestane 1dalpiciclib 1Tamoxifen 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × HR Positive HER2 Negative Advanced Breast Cancer × Letrozole × Clear all
NCT07285382 2025-12-16

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

The Affiliated Hospital of Qingdao University

Phase 2 Recruiting
120 enrolled
Breast

HR Positive HER2 Negative Advanced Breast Cancer

NCT05890287 2023-06-06

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
60 enrolled
Breast

HR Positive HER2 Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡